Related Experiment Video

Updated: May 24, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

8.6K

PARP1 in melanoma: Mechanistic insights and implications for basic and clinical research

Andrea Marranci1, Luisa Maresca2, Samuele Lodovichi3

  • 1Oncohematology Unit, Fondazione Pisana per la Scienza ONLUS, San Giuliano Terme, 56017, Pisa, Italy. Electronic address: http://www.fpscience.it/.

Cancer Letters
|March 2, 2025
PubMed

Insights

Poly (ADP-ribose) polymerase 1 (PARP1) is crucial in melanoma development. PARP inhibitors show promise for treating melanoma, but further research is needed to optimize their use.

Area of Science:

  • Oncology
  • Cancer Biology
  • Genetics

Background:

  • Metastatic melanoma treatment has been transformed by targeted therapies and immunotherapies.
  • PARP inhibitors (PARPi) have shown success in breast and ovarian cancers.
  • Emerging evidence implicates PARP1 in melanoma initiation and progression.

Purpose of the Study:

  • To review the role of PARP1 in melanoma.
  • To explore the potential of PARP inhibitors in melanoma treatment.
  • To identify challenges and future research directions for PARPi in melanoma.

Main Methods:

  • Literature review of preclinical and clinical studies on PARP1 and PARPi in melanoma.
  • Analysis of the correlation between PARP1 expression and melanoma characteristics.
  • Evaluation of the efficacy of PARPi as monotherapy and in combination treatments.

Main Results:

  • High PARP1 expression is linked to aggressive melanoma and poor patient outcomes.
  • PARPi demonstrate potential in reducing melanoma cell viability and inhibiting tumor growth.
  • Current research on integrating PARPi with existing therapies and patient selection is limited.

Conclusions:

  • PARP1 plays a significant role in melanoma.
  • PARPi represent a promising therapeutic avenue for melanoma.
  • Further basic and clinical research is essential to overcome challenges like treatment resistance and to fully leverage PARPi for melanoma patients.
Keywords:
ImmunotherapyMelanomaPARP1PARPiPatient stratificationTargeted therapy

More Related Videos

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.4K
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.2K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.1K